IsoRay's device for treating recurrent brain tumors, GammaTile therapy, has been granted 510(k) clearance by the FDA. The company has also announced a direct offering of shares of its stock in hopes of raising $8.25 million to be used as working capital, as well as for marketing purposes.
IsoRay secures clearance for GammaTile, announces $8.25M offering
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.